<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528228</url>
  </required_header>
  <id_info>
    <org_study_id>TENS Study #110518-001</org_study_id>
    <nct_id>NCT01528228</nct_id>
  </id_info>
  <brief_title>Effects of TENS Therapy Following Arthroscopic Knee Surgery</brief_title>
  <acronym>TENS</acronym>
  <official_title>Effects of Transcutaneous Electrical Nerve Stimulation (TENS) on Postoperative Pain and Function Following Arthroscopic Knee Surgery: A Prospective Randomized Clinical Trial Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>A.T. Still University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>A.T. Still University of Health Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following standard of care procedures for arthroscopy knee surgery it is anticipated that
      Transcutaneous Electrical Nerve Stimulation (TENS) will provide improved pain relief and
      improve functional outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 1, 2011</start_date>
  <completion_date type="Actual">April 1, 2012</completion_date>
  <primary_completion_date type="Actual">April 1, 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient's Perception of Pain in the Early Post-operative Period While Utilizing Structured TENS Therapy.</measure>
    <time_frame>Two weeks postoperatively.</time_frame>
    <description>The patient participant will record pain levels during the immediate post-op 2-week time period every day. Day 0 is pain level before surgery. Pain perception measured on a scale from 0-10 with 0 representing no or lowest level pain and 10 representing the highest level of pain</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Meniscus Tear</condition>
  <arm_group>
    <arm_group_label>Structured TENS Therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will be given an active TENS unit to use.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TENS Therapy</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>TENS Treatment with functional or disabled unit</intervention_name>
    <description>TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
    <arm_group_label>Sham TENS Therapy</arm_group_label>
    <arm_group_label>Structured TENS Therapy</arm_group_label>
    <other_name>EMPI Select Pain Control System</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-60

          -  BMI&lt;50

          -  No significant joint malalignment

          -  No significant ligamentous instability

          -  No significant radiographic joint space narrowing

          -  No prior significant knee surgery

          -  Unilateral knee surgery

          -  Not workman's compensation

          -  Planned knee arthroscopy for meniscectomy, chondroplasty or synovectomy

        Exclusion Criteria:

          -  Age &lt;18 or &gt;60

          -  BMI &gt; 50

          -  Significant joint malalignment

          -  Significant ligamentous instability

          -  Significant radiographic joint space narrowing

          -  Prior significant knee surgery

          -  Bilateral knee surgery planned

          -  Worker's Compensation

          -  No planned knee arthroscopy for menisectomy, chondroplasty or synovectomy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kevin Marberry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>A.T. Still University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Missouri Sports Medicine and Orthopaedic Surgery</name>
      <address>
        <city>Kirksville</city>
        <state>Missouri</state>
        <zip>63501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Breit R, Van der Wall H. Transcutaneous electrical nerve stimulation for postoperative pain relief after total knee arthroplasty. J Arthroplasty. 2004 Jan;19(1):45-8.</citation>
    <PMID>14716650</PMID>
  </reference>
  <reference>
    <citation>Lewek M, Stevens J, Snyder-Mackler L. The use of electrical stimulation to increase quadriceps femoris muscle force in an elderly patient following a total knee arthroplasty. Phys Ther. 2001 Sep;81(9):1565-71.</citation>
    <PMID>11688592</PMID>
  </reference>
  <reference>
    <citation>Paternostro-Sluga T, Fialka C, Alacamliogliu Y, Saradeth T, Fialka-Moser V. Neuromuscular electrical stimulation after anterior cruciate ligament surgery. Clin Orthop Relat Res. 1999 Nov;(368):166-75.</citation>
    <PMID>10613165</PMID>
  </reference>
  <reference>
    <citation>Wang B, Tang J, White PF, Naruse R, Sloninsky A, Kariger R, Gold J, Wender RH. Effect of the intensity of transcutaneous acupoint electrical stimulation on the postoperative analgesic requirement. Anesth Analg. 1997 Aug;85(2):406-13.</citation>
    <PMID>9249122</PMID>
  </reference>
  <reference>
    <citation>Hargreaves A, Lander J. Use of transcutaneous electrical nerve stimulation for postoperative pain. Nurs Res. 1989 May-Jun;38(3):159-61.</citation>
    <PMID>2785684</PMID>
  </reference>
  <reference>
    <citation>Arvidsson I, Eriksson E. Postoperative TENS pain relief after knee surgery: objective evaluation. Orthopedics. 1986 Oct;9(10):1346-51.</citation>
    <PMID>3490659</PMID>
  </reference>
  <reference>
    <citation>Tyler E, Caldwell C, Ghia JN. Transcutaneous electrical nerve stimulation: an alternative approach to the management of postoperative pain. Anesth Analg. 1982 May;61(5):449-56. Review.</citation>
    <PMID>6175251</PMID>
  </reference>
  <reference>
    <citation>Neary JM. Transcutaneous electrical nerve stimulation for the relief of post-incisional surgical pain. AANA J. 1981 Apr;49(2):151-5.</citation>
    <PMID>6111884</PMID>
  </reference>
  <reference>
    <citation>Cooperman AM, Hall B, Mikalacki K, Hardy R, Sardar E. Use of transcutaneous electrical stimulation in the control of postoperative pain. Am J Surg. 1977 Feb;133(2):185-7.</citation>
    <PMID>319697</PMID>
  </reference>
  <reference>
    <citation>Selfe TK, Taylor AG. Acupuncture and osteoarthritis of the knee: a review of randomized, controlled trials. Fam Community Health. 2008 Jul-Sep;31(3):247-54. doi: 10.1097/01.FCH.0000324482.78577.0f. Review.</citation>
    <PMID>18552606</PMID>
  </reference>
  <reference>
    <citation>Eyigör S, Karapolat H, Ibisoğlu U, Durmaz B. [Does transcutaneous electrical nerve stimulation or therapeutic ultrasound increase the effectiveness of exercise for knee osteoarthritis: a randomized controlled study]. Agri. 2008 Jan;20(1):32-40. Turkish.</citation>
    <PMID>18338277</PMID>
  </reference>
  <reference>
    <citation>Cetin N, Aytar A, Atalay A, Akman MN. Comparing hot pack, short-wave diathermy, ultrasound, and TENS on isokinetic strength, pain, and functional status of women with osteoarthritic knees: a single-blind, randomized, controlled trial. Am J Phys Med Rehabil. 2008 Jun;87(6):443-51. doi: 10.1097/PHM.0b013e318174e467.</citation>
    <PMID>18496246</PMID>
  </reference>
  <reference>
    <citation>Burch FX, Tarro JN, Greenberg JJ, Carroll WJ. Evaluating the benefits of patterned stimulation in the treatment of osteoarthritis of the knee: a multi-center, randomized, single-blind, controlled study with an independent masked evaluator. Osteoarthritis Cartilage. 2008 Aug;16(8):865-72. doi: 10.1016/j.joca.2007.11.013. Epub 2008 Feb 8.</citation>
    <PMID>18262443</PMID>
  </reference>
  <reference>
    <citation>Kang RW, Lewis PB, Kramer A, Hayden JK, Cole BJ. Prospective randomized single-blinded controlled clinical trial of percutaneous neuromodulation pain therapy device versus sham for the osteoarthritic knee: a pilot study. Orthopedics. 2007 Jun;30(6):439-45. doi: 10.3928/01477447-20070601-11.</citation>
    <PMID>17598487</PMID>
  </reference>
  <reference>
    <citation>Paker N, Tekdös D, Kesiktas N, Soy D. Comparison of the therapeutic efficacy of TENS versus intra-articular hyaluronic acid injection in patients with knee osteoarthritis: a prospective randomized study. Adv Ther. 2006 Mar-Apr;23(2):342-53.</citation>
    <PMID>16751166</PMID>
  </reference>
  <reference>
    <citation>Bjordal JM, Lopes-Martins RA, Bogen B, Johnson M. Physical treatments have valuable role in osteoarthritis. BMJ. 2006 Apr 8;332(7545):853.</citation>
    <PMID>16601058</PMID>
  </reference>
  <reference>
    <citation>Casimiro L, Barnsley L, Brosseau L, Milne S, Robinson VA, Tugwell P, Wells G. Acupuncture and electroacupuncture for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003788. Review.</citation>
    <PMID>16235342</PMID>
  </reference>
  <reference>
    <citation>Law PP, Cheing GL, Tsui AY. Does transcutaneous electrical nerve stimulation improve the physical performance of people with knee osteoarthritis? J Clin Rheumatol. 2004 Dec;10(6):295-9.</citation>
    <PMID>17043536</PMID>
  </reference>
  <reference>
    <citation>Law PP, Cheing GL. Optimal stimulation frequency of transcutaneous electrical nerve stimulation on people with knee osteoarthritis. J Rehabil Med. 2004 Sep;36(5):220-5.</citation>
    <PMID>15626162</PMID>
  </reference>
  <reference>
    <citation>Cheing GL, Hui-Chan CW. Would the addition of TENS to exercise training produce better physical performance outcomes in people with knee osteoarthritis than either intervention alone? Clin Rehabil. 2004 Aug;18(5):487-97.</citation>
    <PMID>15293483</PMID>
  </reference>
  <reference>
    <citation>Talbot LA, Gaines JM, Ling SM, Metter EJ. A home-based protocol of electrical muscle stimulation for quadriceps muscle strength in older adults with osteoarthritis of the knee. J Rheumatol. 2003 Jul;30(7):1571-8.</citation>
    <PMID>12858461</PMID>
  </reference>
  <reference>
    <citation>Cheing GL, Tsui AY, Lo SK, Hui-Chan CW. Optimal stimulation duration of tens in the management of osteoarthritic knee pain. J Rehabil Med. 2003 Mar;35(2):62-8.</citation>
    <PMID>12691335</PMID>
  </reference>
  <reference>
    <citation>Hopkins J, Ingersoll CD, Edwards J, Klootwyk TE. Cryotherapy and Transcutaneous Electric Neuromuscular Stimulation Decrease Arthrogenic Muscle Inhibition of the Vastus Medialis After Knee Joint Effusion. J Athl Train. 2002 Mar;37(1):25-31.</citation>
    <PMID>12937440</PMID>
  </reference>
  <reference>
    <citation>Cheing GL, Hui-Chan CW, Chan KM. Does four weeks of TENS and/or isometric exercise produce cumulative reduction of osteoarthritic knee pain? Clin Rehabil. 2002 Nov;16(7):749-60.</citation>
    <PMID>12428824</PMID>
  </reference>
  <reference>
    <citation>Osiri M, Welch V, Brosseau L, Shea B, McGowan J, Tugwell P, Wells G. Transcutaneous electrical nerve stimulation for knee osteoarthritis. Cochrane Database Syst Rev. 2000;(4):CD002823. Review. Update in: Cochrane Database Syst Rev. 2009;(4):CD002823.</citation>
    <PMID>11034768</PMID>
  </reference>
  <reference>
    <citation>Yurtkuran M, Kocagil T. TENS, electroacupuncture and ice massage: comparison of treatment for osteoarthritis of the knee. Am J Acupunct. 1999;27(3-4):133-40.</citation>
    <PMID>10729968</PMID>
  </reference>
  <reference>
    <citation>Brandt KD. The importance of nonpharmacologic approaches in management of osteoarthritis. Am J Med. 1998 Jul 27;105(1B):39S-44S. Review.</citation>
    <PMID>9715833</PMID>
  </reference>
  <reference>
    <citation>Hunt SA, Jazrawi LM, Sherman OH. Arthroscopic management of osteoarthritis of the knee. J Am Acad Orthop Surg. 2002 Sep-Oct;10(5):356-63.</citation>
    <PMID>12374486</PMID>
  </reference>
  <reference>
    <citation>Taylor P, Hallett M, Flaherty L. Treatment of osteoarthritis of the knee with transcutaneous electrical nerve stimulation. Pain. 1981 Oct;11(2):233-40.</citation>
    <PMID>7033891</PMID>
  </reference>
  <reference>
    <citation>Drosos GI, Stavropoulos NI, Katsis A, Kesidis K, Kazakos K, Verettas DA. Post-operative pain after knee arthroscopy and related factors. Open Orthop J. 2008 Jun 13;2:110-4. doi: 10.2174/1874325000802010110.</citation>
    <PMID>19478890</PMID>
  </reference>
  <reference>
    <citation>Sinatra RS, Torres J, Bustos AM. Pain management after major orthopaedic surgery: current strategies and new concepts. J Am Acad Orthop Surg. 2002 Mar-Apr;10(2):117-29. Review.</citation>
    <PMID>11929206</PMID>
  </reference>
  <reference>
    <citation>Phillips WJ, Currier BL. Analgesic pharmacology: II. Specific analgesics. J Am Acad Orthop Surg. 2004 Jul-Aug;12(4):221-33. Review.</citation>
    <PMID>15473674</PMID>
  </reference>
  <reference>
    <citation>Phillips WJ, Currier BL. Analgesic pharmacology: I. Neurophysiology. J Am Acad Orthop Surg. 2004 Jul-Aug;12(4):213-20. Review.</citation>
    <PMID>15473673</PMID>
  </reference>
  <reference>
    <citation>Suzuki M, Yamada S, Inamura A, Omori Y, Kirimoto H, Sugimura S, Miyamoto M. Reliability and validity of measurements of knee extension strength obtained from nursing home residents with dementia. Am J Phys Med Rehabil. 2009 Nov;88(11):924-33. doi: 10.1097/PHM.0b013e3181ae1003.</citation>
    <PMID>19661779</PMID>
  </reference>
  <reference>
    <citation>Mahony K, Hunt A, Daley D, Sims S, Adams R. Inter-tester reliability and precision of manual muscle testing and hand-held dynamometry in lower limb muscles of children with spina bifida. Phys Occup Ther Pediatr. 2009;29(1):44-59. doi: 10.1080/01942630802574858.</citation>
    <PMID>19197758</PMID>
  </reference>
  <reference>
    <citation>Katz-Leurer M, Rottem H, Meyer S. Hand-held dynamometry in children with traumatic brain injury: within-session reliability. Pediatr Phys Ther. 2008 Fall;20(3):259-63. doi: 10.1097/PEP.0b013e3181824782.</citation>
    <PMID>18703964</PMID>
  </reference>
  <reference>
    <citation>Bell DR, Padua DA, Clark MA. Muscle strength and flexibility characteristics of people displaying excessive medial knee displacement. Arch Phys Med Rehabil. 2008 Jul;89(7):1323-8. doi: 10.1016/j.apmr.2007.11.048.</citation>
    <PMID>18586134</PMID>
  </reference>
  <reference>
    <citation>Lu TW, Hsu HC, Chang LY, Chen HL. Enhancing the examiner's resisting force improves the reliability of manual muscle strength measurements: comparison of a new device with hand-held dynamometry. J Rehabil Med. 2007 Nov;39(9):679-84.</citation>
    <PMID>17999004</PMID>
  </reference>
  <reference>
    <citation>Crompton J, Galea MP, Phillips B. Hand-held dynamometry for muscle strength measurement in children with cerebral palsy. Dev Med Child Neurol. 2007 Feb;49(2):106-11.</citation>
    <PMID>17253996</PMID>
  </reference>
  <reference>
    <citation>O'Shea SD, Taylor NF, Paratz JD. Measuring muscle strength for people with chronic obstructive pulmonary disease: retest reliability of hand-held dynamometry. Arch Phys Med Rehabil. 2007 Jan;88(1):32-6.</citation>
    <PMID>17207672</PMID>
  </reference>
  <reference>
    <citation>Bohannon RW. Hand-held dynamometry: adoption 1900-2005. Percept Mot Skills. 2006 Aug;103(1):3-4.</citation>
    <PMID>17037637</PMID>
  </reference>
  <reference>
    <citation>Li RC, Jasiewicz JM, Middleton J, Condie P, Barriskill A, Hebnes H, Purcell B. The development, validity, and reliability of a manual muscle testing device with integrated limb position sensors. Arch Phys Med Rehabil. 2006 Mar;87(3):411-7.</citation>
    <PMID>16500178</PMID>
  </reference>
  <reference>
    <citation>Roy MA, Doherty TJ. Reliability of hand-held dynamometry in assessment of knee extensor strength after hip fracture. Am J Phys Med Rehabil. 2004 Nov;83(11):813-8.</citation>
    <PMID>15502733</PMID>
  </reference>
  <reference>
    <citation>Piao C, Yoshimoto N, Shitama H, Makino K, Wada F, Hachisuka K. Validity and reliability of the measurement of the quardriceps femoris muscle strength with a hand-held dynamometer on the affected side in hemiplegic patients. J UOEH. 2004 Mar 1;26(1):1-11.</citation>
    <PMID>15038067</PMID>
  </reference>
  <reference>
    <citation>Taylor NF, Dodd KJ, Graham HK. Test-retest reliability of hand-held dynamometric strength testing in young people with cerebral palsy. Arch Phys Med Rehabil. 2004 Jan;85(1):77-80.</citation>
    <PMID>14970972</PMID>
  </reference>
  <reference>
    <citation>Wright RW. Knee injury outcomes measures. J Am Acad Orthop Surg. 2009 Jan;17(1):31-9. Review.</citation>
    <PMID>19136425</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 7, 2012</study_first_posted>
  <results_first_submitted>October 10, 2018</results_first_submitted>
  <results_first_submitted_qc>January 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 11, 2019</results_first_posted>
  <last_update_submitted>January 10, 2019</last_update_submitted>
  <last_update_submitted_qc>January 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01528228/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 1, 2011</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT01528228/ICF_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Structured TENS Therapy</title>
          <description>This group will be given an active TENS unit to use.
TENS Treatment with functional or disabled unit: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
        </group>
        <group group_id="P2">
          <title>Sham TENS Therapy</title>
          <description>This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
TENS Treatment with functional or disabled unit: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Structured TENS Therapy</title>
          <description>This group will be given an active TENS unit to use.
TENS Treatment with functional or disabled unit: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
        </group>
        <group group_id="B2">
          <title>Sham TENS Therapy</title>
          <description>This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
TENS Treatment with functional or disabled unit: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.6" spread="9.0"/>
                    <measurement group_id="B2" value="53.3" spread="7.0"/>
                    <measurement group_id="B3" value="50.0" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Patient's Perception of Pain in the Early Post-operative Period While Utilizing Structured TENS Therapy.</title>
        <description>The patient participant will record pain levels during the immediate post-op 2-week time period every day. Day 0 is pain level before surgery. Pain perception measured on a scale from 0-10 with 0 representing no or lowest level pain and 10 representing the highest level of pain</description>
        <time_frame>Two weeks postoperatively.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Structured TENS Therapy</title>
            <description>This group will be given an active TENS unit to use.
TENS Treatment with functional or disabled unit: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
          </group>
          <group group_id="O2">
            <title>Sham TENS Therapy</title>
            <description>This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
TENS Treatment with functional or disabled unit: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Perception of Pain in the Early Post-operative Period While Utilizing Structured TENS Therapy.</title>
          <description>The patient participant will record pain levels during the immediate post-op 2-week time period every day. Day 0 is pain level before surgery. Pain perception measured on a scale from 0-10 with 0 representing no or lowest level pain and 10 representing the highest level of pain</description>
          <units>score on 0-10 pain level scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" lower_limit="3.16" upper_limit="7.04"/>
                    <measurement group_id="O2" value="5.24" lower_limit="3.25" upper_limit="7.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" lower_limit="2.81" upper_limit="6.56"/>
                    <measurement group_id="O2" value="4.07" lower_limit="2.19" upper_limit="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.41" lower_limit="1.54" upper_limit="5.28"/>
                    <measurement group_id="O2" value="3.28" lower_limit="1.41" upper_limit="5.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.78" lower_limit="0.91" upper_limit="4.66"/>
                    <measurement group_id="O2" value="2.95" lower_limit="1.09" upper_limit="4.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.49" lower_limit="0.62" upper_limit="4.37"/>
                    <measurement group_id="O2" value="3.22" lower_limit="1.36" upper_limit="5.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.13" upper_limit="4.88"/>
                    <measurement group_id="O2" value="3.26" lower_limit="1.40" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.20" lower_limit="0.33" upper_limit="4.07"/>
                    <measurement group_id="O2" value="2.72" lower_limit="0.85" upper_limit="4.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="0.55" upper_limit="4.29"/>
                    <measurement group_id="O2" value="2.78" lower_limit="0.92" upper_limit="4.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.12" lower_limit="1.25" upper_limit="5.00"/>
                    <measurement group_id="O2" value="2.63" lower_limit="0.77" upper_limit="4.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 9</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" lower_limit="0.72" upper_limit="4.46"/>
                    <measurement group_id="O2" value="2.35" lower_limit="0.48" upper_limit="4.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 10</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.85" lower_limit="0.97" upper_limit="4.72"/>
                    <measurement group_id="O2" value="2.30" lower_limit="0.44" upper_limit="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 11</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" lower_limit="0.75" upper_limit="4.49"/>
                    <measurement group_id="O2" value="2.93" lower_limit="1.06" upper_limit="4.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.50" lower_limit="0.62" upper_limit="4.37"/>
                    <measurement group_id="O2" value="2.66" lower_limit="0.78" upper_limit="4.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 13</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" lower_limit="0.53" upper_limit="4.31"/>
                    <measurement group_id="O2" value="3.02" lower_limit="1.13" upper_limit="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" lower_limit="0.41" upper_limit="4.25"/>
                    <measurement group_id="O2" value="3.20" lower_limit="1.27" upper_limit="5.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <desc>Transcutaneous Electrical Nerve Stimulation (TENS) therapy is considered an appropriate non-pharmacologic adjunct for the treatment of symptomatic knee arthritis. Since the electrical stimulation applied is minimal, the participants were at no risk of adverse events.</desc>
      <group_list>
        <group group_id="E1">
          <title>Structured TENS Therapy</title>
          <description>This group will be given an active TENS unit to use.
TENS Treatment with functional or disabled unit: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
        </group>
        <group group_id="E2">
          <title>Sham TENS Therapy</title>
          <description>This group will receive a placebo TENS unit which has been functionally disabled to provide a short initial electrical impulse then cease delivering that impulse.
TENS Treatment with functional or disabled unit: TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Corey Luebbering</name_or_title>
      <organization>A.T. Still University</organization>
      <phone>660.626.2147</phone>
      <email>coreyluebbering@atsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

